Abbas Hussain - 30 Apr 2026 Form 4 Insider Report for Moderna, Inc. (MRNA)

Reporting relationship: Director
Issuer ticker: MRNA
Reported as of: 30 Apr 2026
Net transaction value: -$264,952
SEC form: 4
Accepted by SEC: 04 May 2026, 17:25:09 UTC
Prior SEC filing: 11 Dec 2025
Next SEC filing: 08 May 2026
Source filing: View source filing
Reporting owner signature: /s/ James Dillon, As Attorney-in-Fact

Key filing fact

Abbas Hussain filed Form 4 for Moderna, Inc. (MRNA) on 04 May 2026.

Key facts

This page summarizes Abbas Hussain's Form 4 filing for Moderna, Inc. (MRNA).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 May 2026, 17:25.

Change

Previous filing in this sequence was filed on 11 Dec 2025.
Current net transaction value: -$264,952.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001821956 Primary reporting owner

Hussain Abbas

Relationship: Director
Address: C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE
Signature: /s/ James Dillon, As Attorney-in-Fact
Signature date: 04 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRNA transaction

Common Stock

Options Exercise

Transaction value
Shares: +16,233
Change %: +1071%
Price
Shares after: 17,748
Date: 30 Apr 2026
Ownership: Direct
Footnotes: F1

MRNA transaction

Common Stock

Sale

Transaction value: $264,952
Shares: -5,682
Change %: -32%
Price: $46.63
Shares after: 12,066
Date: 01 May 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRNA transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -16,233
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 30 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,233
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Restricted stock units convert into common stock on a one-for-one basis.

Footnote F2

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on September 5, 2025. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

Footnote F3

The shares subject to this restricted stock unit award vested in full on April 30, 2026.